Financial Performance - The company's revenue for Q3 2024 reached ¥2,152,363,696.50, representing a 4.68% increase compared to ¥2,056,169,962.39 in the same period last year[2]. - Net profit attributable to shareholders was ¥238,367,803.44, a 17.02% increase from ¥203,700,403.17 year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥239,550,061.24, up 24.76% from ¥192,012,357.18 in the previous year[2]. - The company reported a basic earnings per share of ¥0.45, up 15.38% from ¥0.39 in the same period last year[2]. - The net profit for Q3 2024 reached CNY 690,576,353.68, an increase of 20% compared to CNY 575,117,905.89 in Q3 2023[17]. - Basic earnings per share increased to CNY 1.22 from CNY 1.04 year-over-year[18]. - Operating profit for the quarter was CNY 911,469,828.60, up from CNY 756,906,332.63 in the same period last year, reflecting a growth of approximately 20%[17]. - The total comprehensive income for the quarter was CNY 688,979,437.14, an increase from CNY 575,405,662.89 in the same quarter last year[17]. - The company recorded a total profit of CNY 907,916,950.83 for the quarter, up from CNY 756,828,854.82 in Q3 2023[17]. Cash Flow and Assets - The company's cash flow from operating activities for the year-to-date was ¥562,424,238.63, an increase of 24.91% compared to ¥450,256,050.68 last year[2]. - Cash and cash equivalents at the end of the period totaled CNY 1,037,953,705.98, compared to CNY 872,466,509.71 at the end of Q3 2023[20]. - The net cash flow from operating activities was CNY 562,424,238.63, up from CNY 450,256,050.68 in Q3 2023, representing a growth of about 25%[19]. - The company reported a net cash outflow from investing activities of CNY 510,436,795.07, worsening from a net outflow of CNY 314,484,417.89 in the previous year[20]. - The company's total assets at the end of the reporting period were ¥6,896,388,160.04, reflecting a 7.46% increase from the previous year[2]. - Current liabilities rose significantly to ¥3,135,223,401.29 from ¥2,391,555,195.75, marking an increase of approximately 31.0%[14]. - The company's total equity decreased to ¥2,515,198,587.64 from ¥3,119,452,619.76, a decline of about 19.4%[15]. - The cash and cash equivalents decreased to ¥1,270,692,224.30 from ¥1,344,444,507.80, a decline of about 5.5%[14]. - The company reported a significant increase in trading financial assets to ¥183,384,125.78 from ¥27,617,099.81, reflecting a growth of approximately 563.5%[14]. - Long-term equity investments rose to ¥323,496,875.76 from ¥239,446,916.45, indicating an increase of about 35.1%[14]. Business Segments - The core brand operation business generated revenue of ¥4,133,000,000, a 15.48% increase year-on-year, with a gross profit margin of 91.93%[6]. - Wholesale and distribution business revenue decreased by 19.38% to ¥1,703,000,000 due to a focus on core brand operations[6]. - Retail business revenue increased by 8.56% to ¥289,000,000 compared to the previous year[7]. - Total revenue for the period reached ¥6,143,923,658.27, an increase of 2.66% compared to ¥5,985,061,086.98 in the previous period[16]. - Operating costs amounted to ¥5,252,717,606.61, slightly up from ¥5,251,722,166.22, indicating a marginal increase in operational expenses[16]. - Research and development expenses decreased to ¥19,683,970.50 from ¥29,726,109.92, reflecting a reduction of approximately 33.9%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,138[8]. - Baiyang Pharmaceutical Group Co., Ltd. holds 70.22% of the shares, amounting to 369,077,400 shares[8]. - The company’s major shareholders include Beijing Baiyang Chengchuang Pharmaceutical Investment Co., Ltd. with a 3.81% stake, equating to 20,000,000 shares[8]. - Tianjin Huitong Asset Management Partnership holds 1.09% of the shares, which is 5,730,750 shares[8]. - The top ten shareholders did not participate in margin trading or securities lending activities[9]. Acquisitions and Future Outlook - The company completed the acquisition of a 60.199% stake in Shanghai Baiyang Pharmaceutical Co., Ltd. for a total transaction price of 880.036073 million RMB[11]. - The first batch of restricted shares totaling 406,725,000 shares has been released from restrictions as of July 3, 2024[10]. - The company has expanded its product structure and industry chain layout in line with national traditional Chinese medicine development strategies[11]. - The company has a total of 88,003.6073 million RMB in completed transactions related to acquisitions[11]. - The company’s future outlook includes further market expansion and product development initiatives[12].
百洋医药(301015) - 2024 Q3 - 季度财报